- Home
- IMUX vs CPHC Comparison
IMUX vs CPHC Comparison
Compare IMUX & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- CPHC
- Stock Information
- Founded
- IMUX 2016
- CPHC 1994
- Country
- IMUX United States
- CPHC United States
- Employees
- IMUX N/A
- CPHC N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- IMUX Health Care
- CPHC Consumer Discretionary
- Exchange
- IMUX Nasdaq
- CPHC Nasdaq
- Market Cap
- IMUX 100.0M
- CPHC 109.9M
- IPO Year
- IMUX N/A
- CPHC 1994
- Fundamental
- Price
- IMUX $1.07
- CPHC $21.00
- Analyst Decision
- IMUX Strong Buy
- CPHC
- Analyst Count
- IMUX 6
- CPHC 0
- Target Price
- IMUX $12.67
- CPHC N/A
- AVG Volume (30 Days)
- IMUX 885.0K
- CPHC 3.1K
- Earning Date
- IMUX 02-20-2025
- CPHC 11-07-2024
- Dividend Yield
- IMUX N/A
- CPHC 1.33%
- EPS Growth
- IMUX N/A
- CPHC N/A
- EPS
- IMUX N/A
- CPHC 0.94
- Revenue
- IMUX N/A
- CPHC $62,111,814.00
- Revenue This Year
- IMUX N/A
- CPHC N/A
- Revenue Next Year
- IMUX N/A
- CPHC N/A
- P/E Ratio
- IMUX N/A
- CPHC $22.31
- Revenue Growth
- IMUX N/A
- CPHC 0.13
- 52 Week Low
- IMUX $0.97
- CPHC $17.10
- 52 Week High
- IMUX $2.11
- CPHC $30.25
- Technical
- Relative Strength Index (RSI)
- IMUX 45.08
- CPHC 51.26
- Support Level
- IMUX $0.99
- CPHC $20.37
- Resistance Level
- IMUX $1.09
- CPHC $22.50
- Average True Range (ATR)
- IMUX 0.06
- CPHC 0.96
- MACD
- IMUX -0.00
- CPHC -0.10
- Stochastic Oscillator
- IMUX 39.89
- CPHC 34.13
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.